Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group.
The Committee for Medicinal Products for Human Use (CHMP) is currently preparing a guideline on 'methodological issues in confirmatory clinical trials with flexible design and analysis plan'. PSI (Statisticians in the Pharmaceutical Industry) sponsored a meeting of pharmaceutical statisticians with an interest in the area to share experiences and identify potential opportunities for adaptive designs in late-phase clinical drug development. This article outlines the issues raised, resulting discussions and consensus views reached. Adaptive designs have potential utility in late-phase clinical development. Sample size re-estimation seems to be valuable and widely accepted, but should be made independent of the observed treatment effect where possible. Where unblinding is necessary, careful consideration needs to be given to preserving the integrity of the trial. An area where adaptive designs can be particularly beneficial is to allow dose selection in pivotal trials via adding/dropping treatment arms; for example, combining phase II and III of the drug development program. The more adaptations made during a late-phase clinical trial, the less likely that the clinical trial would be considered as a confirmatory trial. In all cases it would be advisable to consult with regulatory agencies at the protocol design stage. All involved should remain open to scientifically valid opportunities to improve drug development.
Phillips
Alan J
AJ
ICON Clinical Research, 2 Globeside, Globeside Business Park, Marlow, Buckinghamshire SL7 1 TB, UK. phillipsa@iconuk.com
Keene
Oliver N
ON
D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D006801:Humans; D012107:Research Design; D018401:Sample Size